{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:09Z","timestamp":1788011229890,"version":"build-2784847793"},"reference-count":172,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007469","name":"Alfred Benzon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:47:29Z","timestamp":1753415249000},"page":"1031-1056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Noomi","family":"Vainer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Katsimigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie Curovic","family":"Rotbain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hoc.2025.05.003_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients","volume":"6","author":"da Cunha-Bang","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","article-title":"Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.003_bib4","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.003_bib5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib6","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.197889","article-title":"Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib7","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"And predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41375-020-0980-0","article-title":"Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study","volume":"35","author":"Andersen","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.003_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13756-022-01067-1","article-title":"Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values","volume":"11","author":"Thornton","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.003_bib13","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.vaccine.2007.10.053","article-title":"Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia","volume":"26","author":"Sinisalo","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2025.05.003_bib16","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2019-121907","volume":"134","author":"da Cunha-Bang","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clml.2023.02.001","article-title":"SOHO state of the art updates and next question | infections in chronic lymphocytic leukema patients: risks and management","volume":"23","author":"Gargiulo","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000533234","article-title":"Immune dysfunction and infection - interaction between CLL and treatment: a reflection on current treatment paradigms and unmet needs","volume":"147","author":"Gargiulo","year":"2024","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.003_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood-2013-08-523704","article-title":"Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding","volume":"123","author":"Shim","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41416-024-02816-2","article-title":"Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma","volume":"131","author":"Packness","year":"2024","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.17857","article-title":"Chronic lymphocytic leukaemia clones are detectable decades before diagnosis","volume":"196","author":"Vojdeman","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/ajh.27367","article-title":"Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations","volume":"99","author":"Langerbeins","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CLEP.S479672","article-title":"The Danish lymphoid cancer research (DALY-CARE) data resource: the Basis for developing data-driven hematology","volume":"17","author":"Brieghel","year":"2025","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.24.00975","article-title":"Ibrutinib in early-stage chronic lymphocytic leukemia: the randomized, placebo-controlled, double-blind, phase III CLL12 trial","volume":"43","author":"Langerbeins","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.003_bib26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib27","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death","volume":"57","author":"Andersen","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib28","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib29","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.196543","article-title":"Immune failure, infection and survival in chronic lymphocytic leukemia","volume":"103","author":"Crassini","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10428194.2021.1973672","article-title":"Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art","volume":"63","author":"Agius","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41746-024-01132-6","article-title":"Deployment and validation of the CLL treatment infection model adjoined to an EHR system","volume":"7","author":"Agius","year":"2024","journal-title":"npj Digit Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.003_bib33","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib34","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26964","article-title":"Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia","volume":"98","author":"Rotbain","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-017-3176-x","article-title":"Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States","volume":"17","author":"Nabhan","year":"2017","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib36","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41375-018-0316-5","article-title":"Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study","volume":"33","author":"Andersen","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib38","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.003_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.003_bib41","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib44","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11912-022-01261-9","article-title":"Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies","volume":"24","author":"Rivera","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2025.05.003_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"issue":"10232","key":"10.1016\/j.hoc.2025.05.003_bib48","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.003_bib49","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2025.05.003_bib51","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.003_bib53","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib54","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0733-8619(02)00066-X","article-title":"Cerebrovascular complications in cancer patients","volume":"21","author":"Rogers","year":"2003","journal-title":"Neurol Clin"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses (Berl)"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib58","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2025.05.003_bib60","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.003_bib61","unstructured":"Eichhorst B. Time-limited venetoclax-obinutuzumab +\/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA\/CLL13 trial. Presented at EHA, Vienna, Austria, June 9-12, 2022."},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib62","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater Arnon","year":"2022","journal-title":"NEJM Evidence"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.003_bib63","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.003_bib64","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib65","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib--findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib66","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib67","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.hoc.2025.05.003_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib69","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib70","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.003_bib71","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib73","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.003_bib74","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"279","key":"10.1016\/j.hoc.2025.05.003_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.003_bib76","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-023-05462-5","article-title":"TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches","volume":"103","author":"Pereira","year":"2024","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.003_bib77","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib78","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.003_bib79","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.003_bib81","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.003_bib82","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.003_bib83","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib84","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1038\/s41598-018-23808-2","article-title":"Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses","volume":"8","author":"Alflen","year":"2018","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.003_bib85","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.2020007376","article-title":"Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy","volume":"137","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.003_bib86","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.003_bib87","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14656566.2020.1751123","article-title":"Duvelisib for the treatment of chronic lymphocytic leukemia","volume":"21","author":"Frustaci","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.003_bib88","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib89","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2943","article-title":"Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management","volume":"40","author":"Eyre","year":"2022","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.003_bib91","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2024-207452","article-title":"Improved efficacy with response- and MRD-guided ibrutinib-obinutuzumab (IO) intensification after ibrutinib-venetoclax (IV) in first line chronic lymphocytic leukemia (CLL) patients: primary analysis of the HOVON 158\/next STEP phase 2 trial","volume":"144","author":"Levin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib92","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for relapsed CLL: phase 2 VISION\/HO141 trial","author":"Niemann","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473656","article-title":"When and how long to treat chronic lymphocytic leukemia?","volume":"45","author":"Niemann","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10402","key":"10.1016\/j.hoc.2025.05.003_bib94","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.003_bib95","doi-asserted-by":"crossref","unstructured":"Danilov A, Fakhri B, Awan FT, et al., Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of epcore CLL-1. Presented at ASH, San Diego, CA, USA, Dec 7-10, 2024.","DOI":"10.1182\/blood-2024-199708"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib96","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/hematology.2021000234","article-title":"Is there a role for anti-CD20 antibodies in CLL?","volume":"2021","author":"Shah","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9747","key":"10.1016\/j.hoc.2025.05.003_bib97","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.003_bib98","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1182\/bloodadvances.2024014121","article-title":"COVID-19 vaccination during therapy in relation to COVID-19 death in CLL","volume":"8","author":"Brown","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib99","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.003_bib100","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.003_bib101","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.003_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133134","article-title":"Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking?","volume":"13","author":"Smolej","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib104","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2022-156070","article-title":"Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): the glow study","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib107","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.1993.tb00165.x","article-title":"Severe immunodeficiency in patients treated with fludarabine monophosphate","volume":"50","author":"Wijermans","year":"1993","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib108","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.","article-title":"Infectious complications in chronic lymphocytic leukemia","volume":"4","author":"Nosari","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.annonc.a058515","article-title":"Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia","volume":"4","author":"Bergmann","year":"1993","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib110","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib111","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib112","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.003_bib113","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.17337","article-title":"Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study","volume":"193","author":"da Cunha-Bang","year":"2021","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.003_bib115","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.003_bib116","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.003_bib117","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.003_bib118","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab","volume":"93","author":"Garc\u00eda Mu\u00f1oz","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib119","doi-asserted-by":"crossref","first-page":"1098326","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2025.05.003_bib120","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2025.05.003_bib121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2025.05.003_bib122","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","article-title":"Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia","volume":"57","author":"Mauro","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2025.05.003_bib123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/00365548.2013.769279","article-title":"Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia","volume":"45","author":"Svensson","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.hoc.2025.05.003_bib124","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.003_bib125","author":"Wierda"},{"key":"10.1016\/j.hoc.2025.05.003_bib126","author":"Pedersen"},{"key":"10.1016\/j.hoc.2025.05.003_bib127","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10238-022-00809-0","article-title":"Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab","volume":"23","author":"Bacova","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.hoc.2025.05.003_bib128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2025.05.003_bib129","doi-asserted-by":"crossref","first-page":"105385","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.hoc.2025.05.003_bib130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2025.05.003_bib131","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.hoc.2025.05.003_bib132","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286942","article-title":"Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia","author":"K\u00e4ttstr\u00f6m","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2025.05.003_bib133","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.hoc.2025.05.003_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.hoc.2025.05.003_bib135","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1016\/j.clml.2022.03.012","article-title":"COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis","volume":"22","author":"Ito","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2025.05.003_bib136","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4161\/hv.29094","article-title":"Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies","volume":"10","author":"Ide","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.hoc.2025.05.003_bib137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-021-01219-7","article-title":"Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia","volume":"15","author":"Parry","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib138","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2025.05.003_bib139","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1080\/10428194.2023.2258243","article-title":"Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL","volume":"64","author":"Tomasulo","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.003_bib140","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3026(25)00008-0","article-title":"A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial","volume":"12","author":"Cook","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib141","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti\u2013COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.003_bib142","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221090150","article-title":"Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study","volume":"13","author":"Diamantopoulos","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib143","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000534540","article-title":"COVID-19 in patients with chronic lymphocytic leukemia: what have we learned?","volume":"147","author":"Harel","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib144","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015260","article-title":"Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era","author":"Hedberg","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.003_bib145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib146","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2025.05.003_bib147","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0953-6205(01)00149-2","article-title":"Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients","volume":"12","author":"van der Velden","year":"2001","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hoc.2025.05.003_bib148","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.vaccine.2021.01.001","article-title":"The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)","volume":"39","author":"Whitaker","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.hoc.2025.05.003_bib149","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41375-020-0884-z","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological malignancies: results from a nationwide 16-year cohort study","volume":"72","author":"Andersen","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.003_bib151","doi-asserted-by":"crossref","first-page":"ofaf069","DOI":"10.1093\/ofid\/ofaf069","article-title":"Immunogenicity and safety of the higher-valent pneumococcal conjugate vaccine vs the 13-valent pneumococcal conjugate vaccine in older adults: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Ngamprasertchai","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.hoc.2025.05.003_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11071201","article-title":"Immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia","volume":"11","author":"Haggenburg","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.hoc.2025.05.003_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 Years: recommendations of the advisory Committee on immunization practices - United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.hoc.2025.05.003_bib154","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ejh.13553","article-title":"A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era","volume":"106","author":"Steingr\u00edmsson","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2025.05.003_bib155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib156","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-025-08800-x","article-title":"A natural experiment on the effect of herpes zoster vaccination on dementia","volume":"641","author":"Eyting","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2025.05.003_bib157","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.003_bib158","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.003_bib160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.003_bib161","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.ejca.2013.07.006","article-title":"Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group","volume":"49","author":"Kim","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2025.05.003_bib162","author":"Society"},{"key":"10.1016\/j.hoc.2025.05.003_bib163","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctim.2019.03.013","article-title":"The effects of physical activity on cancer prevention, treatment and prognosis: a review of the literature","volume":"44","author":"Lugo","year":"2019","journal-title":"Complement Ther Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib164","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-012-2253-8","article-title":"Social networks, social support, and burden in relationships, and mortality after breast cancer diagnosis in the Life after Breast Cancer Epidemiology (LACE) study","volume":"137","author":"Kroenke","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.003_bib165","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bjoms.2020.04.041","article-title":"Loneliness and quality of life after head and neck cancer","volume":"58","author":"Dahill","year":"2020","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.hoc.2025.05.003_bib166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in Oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.003_bib167","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.003_bib168","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.hoc.2025.05.003_bib169","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.003_bib170","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.003_bib171","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.003_bib172","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.003_bib173","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:50:46Z","timestamp":1760503846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":172,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000656"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}